Dexamethasone ophthalmic - EyeGate Pharma

Drug Profile

Dexamethasone ophthalmic - EyeGate Pharma

Alternative Names: Dexamethasone phosphate; EGP-437

Latest Information Update: 07 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EyeGate Pharma
  • Class Anti-inflammatories; Antiemetics; Antineoplastics; Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Keratoplasty rejection
  • New Molecular Entity No

Highest Development Phases

  • Phase III Uveitis
  • Phase II Ocular inflammation
  • Phase I/II Retinal oedema
  • Phase I Retinal disorders
  • Suspended Dry eyes; Scleritis
  • No development reported Keratoplasty rejection

Most Recent Events

  • 06 Sep 2018 Updated efficacy data from a phase III trial in Uveitis released by EyeGate Pharma
  • 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
  • 29 May 2018 EyeGate Pharma completes a phase III trial for Uveitis in USA (NCT02517619)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top